AGY Therapeutics, Inc. Appoints President & Chief Operating Officer

Apr 23, 2001, 01:00 ET from AGY Therapeutics, Inc.

    SOUTH SAN FRANCISCO, Calif., April 23 /PRNewswire Interactive News
 Release/ -- AGY Therapeutics, Inc. today announced the appointment of
 Philip J. Young as president and chief operating officer.  Young will assume
 his new responsibilities immediately.
     "Philip's broad experience in product development and commercialization
 will be instrumental in our efforts to transition from primary research to
 drug development," said Karoly Nikolich, founder and chief executive officer
 of AGY Therapeutics.  "I am confident that his 21 years of industry knowledge
 will bring significant leadership and management expertise to the solid
 execution of our business strategy."
     Young comes to AGY Therapeutics from GanTech International, a
 venture-backed protein technology company in the San Francisco Bay Area, where
 he was chief executive officer.  Before joining GanTech International, Young
 served for four years at Neurex Pharmaceuticals, currently a division of Elan
 Corporation, plc.  He joined Neurex as vice president of sales and marketing
 and later was promoted to vice president and general manager.  Prior, Young
 worked at Pharmacia, Inc. and Gilead Sciences, Inc., where he held senior
 marketing and sales management positions.  Young also spent seven years at
 Genentech, Inc. where he was the product manager of growth hormone products
 and a clinical marketing specialist.  Young earned a bachelor's degree from
 James Madison University.
     AGY Therapeutics, Inc. is a biotechnology company dedicated to the
 discovery and development of innovative treatments for central nervous system
 dysfunction.  The company employs "sequential molecular snapshots" to analyze
 models of central nervous system diseases and to identify novel therapeutics
 that interfere with the intra- and extra-cellular signaling (mechanistic)
 pathways underlying the pathology of these diseases.  For more information
 about AGY Therapeutics, please visit www.agyinc.com.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X42452892
 
 

SOURCE AGY Therapeutics, Inc.
    SOUTH SAN FRANCISCO, Calif., April 23 /PRNewswire Interactive News
 Release/ -- AGY Therapeutics, Inc. today announced the appointment of
 Philip J. Young as president and chief operating officer.  Young will assume
 his new responsibilities immediately.
     "Philip's broad experience in product development and commercialization
 will be instrumental in our efforts to transition from primary research to
 drug development," said Karoly Nikolich, founder and chief executive officer
 of AGY Therapeutics.  "I am confident that his 21 years of industry knowledge
 will bring significant leadership and management expertise to the solid
 execution of our business strategy."
     Young comes to AGY Therapeutics from GanTech International, a
 venture-backed protein technology company in the San Francisco Bay Area, where
 he was chief executive officer.  Before joining GanTech International, Young
 served for four years at Neurex Pharmaceuticals, currently a division of Elan
 Corporation, plc.  He joined Neurex as vice president of sales and marketing
 and later was promoted to vice president and general manager.  Prior, Young
 worked at Pharmacia, Inc. and Gilead Sciences, Inc., where he held senior
 marketing and sales management positions.  Young also spent seven years at
 Genentech, Inc. where he was the product manager of growth hormone products
 and a clinical marketing specialist.  Young earned a bachelor's degree from
 James Madison University.
     AGY Therapeutics, Inc. is a biotechnology company dedicated to the
 discovery and development of innovative treatments for central nervous system
 dysfunction.  The company employs "sequential molecular snapshots" to analyze
 models of central nervous system diseases and to identify novel therapeutics
 that interfere with the intra- and extra-cellular signaling (mechanistic)
 pathways underlying the pathology of these diseases.  For more information
 about AGY Therapeutics, please visit www.agyinc.com.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X42452892
 
 SOURCE  AGY Therapeutics, Inc.